Gilder Gagnon Howe & Co. LLC trimmed its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 18.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,539,452 shares of the medical research company’s stock after selling 589,163 shares during the quarter. Exact Sciences Corporation comprises about 1.7% of Gilder Gagnon Howe & Co. LLC’s investment portfolio, making the stock its 11th largest holding. Gilder Gagnon Howe & Co. LLC owned approximately 2.12% of Exact Sciences Corporation worth $119,659,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Fortaleza Asset Management Inc. acquired a new position in shares of Exact Sciences Corporation during the second quarter valued at about $106,000. Krilogy Financial LLC increased its holdings in shares of Exact Sciences Corporation by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 3,650 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 600 shares in the last quarter. Crescent Grove Advisors LLC acquired a new position in shares of Exact Sciences Corporation during the third quarter valued at about $200,000. Finally, Financial Architects Inc increased its holdings in shares of Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after acquiring an additional 2,035 shares in the last quarter. 85.65% of the stock is owned by institutional investors and hedge funds.

EXAS has been the topic of several recent analyst reports. Vetr upgraded shares of Exact Sciences Corporation from a “sell” rating to a “buy” rating and set a $41.07 price objective on the stock in a report on Wednesday, August 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $45.00 price target (up previously from $42.00) on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Bank of America Corporation reiterated a “buy” rating on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Roth Capital increased their price target on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Craig Hallum reiterated a “buy” rating and issued a $46.00 price target (up previously from $41.00) on shares of Exact Sciences Corporation in a report on Wednesday, July 26th. Eight equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $49.98.

TRADEMARK VIOLATION WARNING: “Gilder Gagnon Howe & Co. LLC Lowers Position in Exact Sciences Corporation (EXAS)” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/gilder-gagnon-howe-co-llc-lowers-position-in-exact-sciences-corporation-exas/1700678.html.

Shares of Exact Sciences Corporation (EXAS) traded up $1.19 during mid-day trading on Monday, reaching $60.37. The company’s stock had a trading volume of 1,352,200 shares, compared to its average volume of 2,562,707. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $63.60.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings data on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.07. The company had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm’s revenue for the quarter was up 158.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) EPS. sell-side analysts expect that Exact Sciences Corporation will post -1.14 EPS for the current year.

In other Exact Sciences Corporation news, SVP D Scott Coward sold 29,115 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the sale, the senior vice president now directly owns 64,991 shares of the company’s stock, valued at approximately $3,064,975.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas D. Carey bought 2,500 shares of the business’s stock in a transaction on Thursday, August 17th. The stock was bought at an average cost of $37.71 per share, with a total value of $94,275.00. Following the completion of the purchase, the director now directly owns 60,858 shares in the company, valued at $2,294,955.18. The disclosure for this purchase can be found here. Insiders sold a total of 277,373 shares of company stock worth $12,635,570 in the last 90 days. 4.00% of the stock is currently owned by insiders.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.